The FREEDOM score performs well in predicting 5-year major adverse cardiovascular events (MACE) for percutaneous coronary intervention (PCI) but has only moderate discrimination and calibration for coronary artery bypass grafting (CABG), according to a new external validation analysis, which also identified heterogeneity of treatment benefit.